All In Biotech

Drug Trial Radar · NCT07287137

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

IDCRP-154: Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Nov 12, 2025

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Centers for Disease Control and Prevention; Food and Drug Administration (FDA)
First posted
Dec 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2026 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.

Conditions

  • COVID -19
  • COVID - 19
  • COVID 19
  • Influenza
  • Respiratory Virus
  • Respiratory Viruses
  • Respiratory Virus Infection
  • Respiratory Virus Infections

Interventions

  • Pfizer-BioNTech mRNA COVID-19 vaccineDrug

    COVID-19 Vaccine, mRNA

  • Novavax recombinant protein vaccineDrug

    Recombinant protein vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Variant-specific immune responses (Year 2 Only)Time frame: IgG binding antibody levels and neutralizing antibody titers will be assessed on serum samples obtained just prior to vaccination, 30 days (+/- 10 days), and 150 days (+/- 10 days) after vaccination.
  2. Variant-specific immune responses (Year 1 Only)Time frame: IgG binding antibody levels and neutralizing antibody titers will be assessed on serum samples obtained just prior to vaccination and 30 days (+/- 10 days after vaccination).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Walter Reed National Military Medical Center

    Bethesda, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.